GlassScriptPhysician profile
Archana C Shende
NPI 1043255938
$14,998.56
in general payments reported to CMS, 2019-2025
44 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $2,758 · 2021: $1,986 · 2022: $2,091 · 2023: $2,636 · 2024: $1,702 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,942 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,942.23 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,643.29 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $1,378.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,140.09 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $1,070.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,037.21 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $980.10 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $719.92 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $677.12 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Esperion Therapeutics, INC. | $579.59 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $516.56 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $490.68 | 2022-2025 | |
| Radius Health, INC. | $442.88 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.38 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $360.64 | 2019-2024 | Veozah |
| Amarin Pharma, INC. | $346.42 | 2019-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $289.31 | 2021-2025 | |
| Corcept Therapeutics | $269.16 | 2022-2024 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.28 | 2019-2025 | Jardiance |
| Ardelyx, INC. | $207.68 | 2024-2025 | Ibsrela |
| Sanofi-Aventis U.S. LLC | $171.46 | 2019-2022 | |
| Exact Sciences Corporation | $138.82 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $123.94 | 2019-2021 | |
| Eisai INC. | $107.15 | 2020-2021 | |
| Edwards Lifesciences Corporation | $83.13 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Biohaven Pharmaceutical Holding Company LTD. | $56.63 | 2022 | |
| Allergan, INC. | $54.22 | 2019-2020 | |
| Lundbeck LLC | $46.03 | 2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $45.80 | 2019-2020 | |
| Abiomed | $43.62 | 2025 | |
| Dexcom, INC. | $42.82 | 2023-2024 | Dexcom G6 Transmitter |
| Regeneron Healthcare Solutions, INC. | $28.14 | 2020 | |
| Abbott Laboratories | $27.36 | 2022 | |
| Antares Pharma, INC. | $23.49 | 2019 | |
| Seqirus USA INC | $22.30 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Lexicon Pharmaceuticals, INC. | $21.54 | 2023 | Inpefa |
| Sumitomo Pharma America, INC. | $16.63 | 2024 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $15.71 | 2021 | |
| Cipher Pharmaceuticals US LLC | $15.66 | 2025 | Natroba, Spinosad |
| Redhill Biopharma INC. | $15.44 | 2020 | |
| Currax Pharmaceuticals LLC | $14.35 | 2025 | Contrave |
| Kowa Pharmaceuticals America, INC. | $14.16 | 2021 | |
| Sunovion Pharmaceuticals INC. | $13.95 | 2021 | |
| Medicure Pharma INC. | $12.92 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Archana Shende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.